No aptamer bench, or a small-molecule target that's stalled elsewhere? Bring the target — we run the full SELEX in Prof. Juewen Liu's group and hand you a validated binder, Kd and all.
Standing up a SELEX pipeline for one target is months of setup and equipment you don't want to own.
Tiny, low-immunogenicity targets are exactly where standard selections stall — and where capture-SELEX in our lab specializes.
You need a binder with a measured affinity you can build a sensor or assay on — not a list of sequences and hope.
We agree on the target, the counter-targets it must ignore, and the buffer your final assay will run in.
Full selection in the Liu lab — capture-SELEX for small molecules — with the counter-selections that build specificity in.
Each round, our engine ranks candidates by real-buffer structure — so we converge in fewer rounds, not brute force.
We measure Kd, truncate to a minimal binder, and hand over a candidate ready to build on.
Not a sequencing pool — a finished, characterized aptamer, with the evidence a partner or investor will ask for.
We assess whether the target is a good fit for aptamer selection — and tell you honestly if it isn't — before anyone commits.
Milestone-based: a deposit to start, and the main fee on delivering a binder that meets an agreed Kd threshold — so the risk is shared, not all yours.
Our strength is small molecules and other hard cases via capture-SELEX — pesticides, toxins, drugs, metabolites. Ask us about proteins and cells; if it's not a fit, we'll say so.
We work that out together up front — and in practice it rarely conflicts. The lab keeps the right to publish the science; you take the aptamer to use directly or build into a sensor or assay. Publication and product use sit side by side. Exact terms by agreement, under NDA.
That's what the milestone structure is for: the bulk of the fee is tied to hitting the agreed Kd, so you're protected on the downside.
Yes — if you have your own bench, the same engine is available as a commercial license. Start on the home page.